Supriya Lifescience is an API manufacturer based in India. It holds 40 active US drug master files across a filed portfolio of 19 molecules. Its GMP standing is certified by EMA and US FDA. Its most recent recorded inspection, by US FDA, closed on 6 February 2026 as VAI. Customs aggregates show $72.0M of exports covering 1,635 molecules to 87 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Mumbai, India | 3003882508 |
| Ratnagiri, India | 3007497376 |
| Khed, India | Not on file |
| Thane, India | 3032073298 |
| Molecule | Regulators | Docs |
|---|---|---|
| Tramadol | US FDA | 4 |
| Chlorpheniramine | SFDA (Saudi Arabia), US FDA | 3 |
| Diphenhydramine | SFDA (Saudi Arabia), US FDA | 3 |
| Albuterol | US FDA | 2 |
| Allopurinol | US FDA | 2 |
| Bisoprolol | US FDA | 2 |
| Brompheniramine | US FDA | 2 |
| Cetirizine | US FDA | 2 |
| Dexchlorpheniramine | US FDA | 2 |
| Dextromethorphan | US FDA | 2 |
| Esketamine | US FDA | 2 |
| Hydroxocobalamin | US FDA | 2 |
| Ketamine | US FDA | 2 |
| Mecobalamin | US FDA | 2 |
| Mepyramine | US FDA | 2 |
| Midazolam | US FDA | 2 |
| Pheniramine | US FDA | 2 |
| Riboflavin | US FDA | 2 |
| Sevoflurane | US FDA | 2 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| MINSA (CR) | 2 | None |
| EMA | None | 1 |
| US FDA | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $14.1M | 58 |
| 2025 | Not reported | $72.0M | 87 |
| 2024 | Not reported | $78.5M | 82 |
| 2023 | Not reported | $53.6M | 83 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Supriya Lifescience comes back tiered against every other supplier able to file there.
Start for free